

Blue Cross Blue Shield of Massachusetts is an Independent Licenses of the Blue Cross and Blue Shield Association

Medical Policy

Implantable Miniature Telescope (IMT)

Table of Contents

- Policy: Commercial
- Policy: Medicare
- <u>Authorization Information</u>
- Coding Information
- Description
- Policy History
- Information Pertaining to All Policies
- References
- Endnotes

Policy Number: 464

BCBSA Reference Number: N/A

NCD/LCD: Local Coverage Determination (LCD): Implantable Miniature Telescope (IMT) (L33584)

Related Policies

None

Policv¹

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

An intraocular telescope (Implantable Miniature Telescope [IMT]) may be <u>MEDICALLY NECESSARY</u> for monocular implantation to improve vision in individuals greater than or equal 65 years of age when all of the following criteria are met:

- The individual must:
 - Achieve at least a 5-letter improvement on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart with an external telescope in the eye scheduled for surgery; and
 - Agree to undergo pre-surgery training and assessment (typically 2 to 4 sessions) with low vision specialists (optometrist or occupational therapist) in the use of an external telescope sufficient for assessment and for the individual to make an informed decision; and
 - o Agree to participate in postoperative visual training with a low vision specialist; and
 - Have adequate peripheral vision in the eye not scheduled for surgery; and
 - Have retinal findings of geographic atrophy or disciform scar with foveal involvement, as determined by fluorescein angiography; and
 - Have stable, severe to profound vision impairment (best corrected distance visual acuity 20/160 to 20/800) caused by bilateral central scotomas, associated with end-stage age-related macular degeneration (AMD); and
 - Show evidence of visually significant cataract (Grade 2 or more).

An intraocular telescope (Implantable Miniature Telescope [IMT]) is **INVESTIGATIONAL** and **NOT MEDICALLY NECESSARY** when all of the above criteria are not met.

Medicare HMO BlueSM and Medicare PPO BlueSM Members

Medical necessity criteria and coding guidance for **Medicare Advantage members living in Massachusetts** can be found through the link(s) below.

Local Coverage Determinations (LCDs) for National Government Services, Inc.

Local Coverage Determination (LCD): Implantable Miniature Telescope (IMT) (L33584)

Note: To review the specific LCD, please remember to click "accept" on the CMS licensing agreement at the bottom of the CMS webpage.

For medical necessity criteria and coding guidance for **Medicare Advantage members living outside of Massachusetts**, please see the Centers for Medicare and Medicaid Services website at https://www.cms.gov for information regarding your specific jurisdiction.

Prior Authorization Information

Inpatient

 For services described in this policy, precertification/preauthorization <u>IS REQUIRED</u> for all products if the procedure is performed **inpatient**.

Outpatient

• For services described in this policy, see below for products where prior authorization <u>might be</u> <u>required</u> if the procedure is performed <u>outpatient</u>.

| | Outpatient | | |
|---------------------------------------|--|--|--|
| Commercial Managed Care (HMO and POS) | Prior authorization is not required . | | |
| Commercial PPO and Indemnity | Prior authorization is not required . | | |
| Medicare HMO Blue SM | Prior authorization is not required . | | |
| Medicare PPO Blue SM | Prior authorization is not required . | | |

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The above <u>medical necessity criteria MUST</u> be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:

CPT Codes

| CPT codes: | Code Description |
|------------|---|
| C1840 | Lens, intraocular (telescopic) |
| 0308T | Insertion of ocular telescope prosthesis including removal of crystalline lens or intraocular lens prosthesis |

Description

The implantable Miniature Telescope (IMT) is a telescope prosthetic device that replaces the natural lens in one eye of patients with bilateral, advanced age-related macular degeneration in order to enlarge the retinal image to such a degree that it is visualized outside of vision-impairing central scotomas.

Policy History

| Date | Action |
|--------|--|
| 5/2020 | Policy updated with literature review through April 2020, references added. Policy statements unchanged. |

| 7/2018 | Medical Policy Administration literature review through June 2018. Policy criteria |
|---------|---|
| | clarified. |
| 1/2016 | Clarified coding information. |
| 8/2015 | Clarified coding language. |
| 12/2013 | New medically necessary and investigational indications described. Effective 12/1/2013. Added ICD-9 diagnosis code 362.52 as it meets the intent of the policy. |
| | Removed LCD: L32275 as it is no longer effective and replaced with LCD: L32454. |
| 8/2013 | New medical policy describing ongoing non-coverage for Commercial. Covered and non-covered indications for Medicare Advantage described. Effective 8/5/2013. |

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

Medical Policy Terms of Use

Managed Care Guidelines

Indemnity/PPO Guidelines

Clinical Exception Process

Medical Technology Assessment Guidelines

References

- 1. Alió JL, Mulet EM, José M. Intraocular telescopic lens evaluation in patients with age-related macular degeneration. J Cataract Refract Surg. 2004 Jun;30(6):1177-89.
- 2. Brown GC, Brown MM, Lieske HB, et al. Comparative Effectiveness and Cost-Effectiveness of the Implantable Miniature Telescope. Ophthalmology. 2011 Sep; 118(9):1834-43.
- 3. Chun DW, Heier JS, Raizman MB. Visual prosthetic device for bilateral end-stage macular degeneration. Expert Rev Med Devices. 2005; 2:657-65.
- Colby KA, Chang DF, Stulting RD, Lane SS. Surgical Placement of an Optical Prosthetic Device for End-Stage Macular Degeneration: The Implantable Miniature Telescope. Arch Ophthalmol. 2007;125(8):1118-1121.
- 5. Garfinkel RA, Berinstein DM, Frantz R. Treatment of choroidal neovascularization through the implantable miniature telescope. Am J Ophthalmol. 2006; 141:766-7.
- 6. Hudson HL, Lane SS, Heier JS, Stulting RD, Singerman L, Lichter PR, Sternberg P, Chang DF. Implantable miniature telescope for the treatment of visual acuity loss due to end-stage age-related macular degeneration: one-year results. Ophthalmology. 2006; 113:1987-2001.
- 7. Hudson HL, Lane SS, Heier JS. Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results. Ophthalmology. 2006 Nov;113(11):1987-2001. Epub 2006 Sep 20.
- Hudson HL, Stulting RD, Heier JS. Implantable telescope for end-stage age-related macular degeneration: long-term visual acuity and safety outcomes. Am J Ophthalmol. 2008 Nov;146(5):664-673
- 9. Lane SS, Kuppermann BD, Fine IH, et al. A prospective multicenter clinical trial to evaluate the safety and effectiveness of the implantable miniature telescope. Am J Ophthalmol. 2004; 137:993-1001.
- 10. Lane SS, Kuppermann BD. The Implantable Miniature Telescope for macular degeneration. Curr Opin Ophthalmol. 2006;17:94-8.
- 11. NHIC CAC
- 12. Peli E. The optical functional advantages of an intraocular low vision telescope. Optom Vis Sci. 2002;79:225-233
- 13. Primo SA. Implantable miniature telescope: lessons learned. Optometry. 2010; 81:86-93.
- 14. Visioncare Application for New Device Category for Transitional Pass-Through Payment Status Under the Hospital Outpatient Prospective Payment SystemFDA approval accessed 9/18/11: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm218066.htm

| _ | - | - | _ | 1 | _ | _ |
|---|---|---|---|---|---|---|
| ы | П | | | т | _ | c |
| | | | | | | |

¹ Based on expert opinion